Trabectedin (YONDELIS), with the English name "trabectedin", is a highly effective therapeutic drug for specific types of tumors. Currently, trabectedin has not been launched in China, nor has it been included in China's medical insurance system. As a result, patients must bear the full cost of treatment themselves. In 2025, the latest price of trabectedin remains at a relatively high level, imposing a heavy financial burden on many patients.
What is the Latest Price of Trabectedin (YONDELIS) in 2025?
Trabectedin has not been marketed in China and is not covered by China's medical insurance. Additionally, there are currently no generic versions of the drug available on the market. As of 2025, the price of trabectedin (YONDELIS) remains relatively expensive.
Price Overview
Taking the original research drug version of trabectedin sold in Turkey as an example, the price of a box (with a specification of 1mg) is approximately 1,354 US dollars. For patients requiring long-term treatment, this cost is undoubtedly a significant financial burden. However, due to the proven clinical efficacy of trabectedin, many patients and their families are still willing to bear this expense to obtain better treatment outcomes.
Influencing Factors
There has been no significant fluctuation in the price of trabectedin. The stability of its price may be attributed to factors such as drug research and development costs, production costs, market demand, and medical insurance policies. For patients, understanding the price trend of trabectedin and its influencing factors helps in better planning treatment expenses and alleviating financial pressure.
Dosage and Administration of Trabectedin (YONDELIS)
During the use of trabectedin, doctors need to adjust the dosage based on the patient's physical condition and the occurrence of adverse reactions.
Recommended Dosage and Administration Route
The recommended dosage of trabectedin is 1.5 mg/m². It is administered via central venous infusion once every 21 days, with each infusion lasting 24 hours.
For patients with moderate liver impairment, the recommended dosage should be reduced to 0.9 mg/m² accordingly.
Patients with severe liver impairment are contraindicated from using trabectedin.
Thirty minutes before each administration, patients need to receive an intravenous injection of 20 mg of dexamethasone to prevent potential allergic reactions.
Dosage Adjustment
For patients who experience persistent adverse reactions or abnormal liver function, temporary suspension of administration, dosage reduction, or permanent discontinuation of the drug may be necessary. Trabectedin may cause a range of adverse reactions, such as nausea, vomiting, fatigue, and constipation. Doctors need to closely monitor the patient's physical condition, promptly address any adverse reactions that may occur, and ensure the patient's safety.
By understanding information regarding the latest price, dosage, and administration of trabectedin, patients can better develop their treatment plans.
